Compare Allegion PLC (ALLE) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Heron Therapeutics Inc — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Heron Therapeutics Inc trades at $0.42 (market cap $79.52M). The key difference: Allegion PLC is far larger — about 147.6× Heron Therapeutics Inc's market cap, and Allegion PLC pays a 1.55% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ALLE | HRTX | |
|---|---|---|
Market Cap | $11.74B | $79.52M |
Sector | Industrials | Health |
52-Week High | $179.77 | $2.18 |
52-Week Low | $125.65 | $0.39 |
Enterprise Value | $13.46B | $177.42M |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.
The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
